NCT01822340View on ClinicalTrials.gov

Safety and Efficacy Study of Recombinant Human Growth Hormone in Adult Growth Hormone Deficiency Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

June 30, 2015

Study Completion Date

February 29, 2016

Conditions
Adult Growth Hormone Deficiency
Interventions
DRUG

HM10560A

Once weekly HM10560A

DRUG

Genotropin

Once daily Genotropin

Trial Locations (1)

Unknown

Hanmi Pharmaceutical, Budapest

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT01822340 - Safety and Efficacy Study of Recombinant Human Growth Hormone in Adult Growth Hormone Deficiency Patients | Biotech Hunter | Biotech Hunter